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Abstract
Background: Previous evidence indicates potential variation in the quality of care of cancer
patients. We aimed to examine whether recent changes in the treatment of oesophagogastric
cancers have been distributed equally among different patient subgroups.
Methods: We analysed population-based cancer registry data about the treatment patterning of
oesophagogastric cancer (other than oesophageal squamous cell carcinoma) during 1995-2006.
Results:  There were 14,077 patients aged ≥40 years (69% men). There was only limited
information on stage, and no information on co-morbidity status. During successive triennia,
curative surgery use decreased from 28% to 20% (p < 0.001) whilst chemotherapy use increased
from 9% to 30% (p < 0.001). Use of palliative surgery and of radiotherapy increased significantly but
modestly (7% to 10%, and 9% to 11%, respectively). In multivariable logistic regression adjusting for
age group, gender, diagnosis period and tumour type, curative surgery and chemotherapy were
used less frequently in more deprived patients [per increasing deprivation group Odds Ratio (OR)
= 0.96, 95% Confidence Interval (CI) 0.93-0.99, and OR = 0.90, 95%CI 0.87-0.93, respectively, p <
0.001 for both)]. Chemotherapy was also used less frequently in women (OR = 0.76, p < 0.001).
Conclusions: During the study period, curative surgery decreased by a third and chemotherapy
use increased by more than three-fold, reflecting improvements in the appropriateness and quality
of management, but chemotherapy use, in particular, was unequal, both by socioeconomic status
and gender.
Background
Oesophageal and stomach cancers [including Oesopha-
geal Squamous Cell Carcinoma (OSCC), Oesophageal
Adeno-Carcinoma (OAC), Junctional/Cardia Adenocarci-
noma (JCA) and Non-Cardia Gastric Adenocarcinoma
(NCGA)] are common. In the UK, they account for over
15,000 new cases per year, and over 13,000 deaths, with
stomach and oesophageal cancers being the 6th and 8th
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most common malignancies in men[1]. Although radical
surgery could offer cure, fewer than a quarter of all
patients present at a stage that can be treated surgically[2].
For suitable patients, peri-operative chemotherapy has
been shown to improve survival[3,4]. This is thought to
have led to a substantial increase in chemotherapy use in
recent years[5].
In recent periods, five-year survival has been <17% for
stomach cancer, and <13% for oesophageal cancer[6-8].
In men with oesophagogastric cancer, survival has been
substantially poorer in more socio-economically deprived
patients[5,7-10]. In contrast, in England and Wales, five-
year relative survival differences between most and least
deprived women were relatively small (-0.2%) for
oesophageal cancer,[8] whereas five-year survival was bet-
ter (+1.7%) in most compared with least deprived women
for stomach cancer[7]. The exact causes of socioeconomic
and gender differences in survival are not known, but in
theory those may reflect differences in clinical manage-
ment, tumour type or stage at presentation, and co-mor-
bidity. Differences in patient (e.g. co-morbidity) or
tumour factors and stage do not seem to fully explain soci-
oeconomic inequalities[11-15]. Conversely, differences in
healthcare may be responsible,[16] and, in some studies,
no survival inequalities were observed when patients were
treated in the same service setting[12,17,18]. However,
overall, the evidence supporting any of the above explana-
tions is limited[13]. A number of high profile policy initi-
atives over recent years in the UK have aimed to focus
efforts on improving outcomes for cancer patients, and on
reducing socioeconomic inequalities in outcomes[19,20].
Motivated by the above considerations, we conducted a
study to examine whether recent changes in the treatment
of oesophagogastric cancers have been distributed equally
among different patient subgroups.
Methods
Non-identifiable information was obtained from the East-
ern Cancer Registration and Information Centre (ECRIC),
one of the regional English population-based cancer reg-
istries, responsible for a general population of about 5.5
million (which is about 10% of the English population)
residing in the East of England Government Office
Region, including the counties of Essex, Bedfordshire,
Hertfordshire, Cambridgeshire, Norfolk and Suffolk and
the Unitary Authorities of Luton and of Peterborough. The
Registry's proportion of 'Death Certificate Only' registra-
tions for all malignancies (which is a useful summary
indicator of good quality of registration processes) has
remained very low during the study period[21].
Information was extracted on East of England residents
aged ≥40 years diagnosed with oesophageal or gastric can-
cer (ICD-10 subsite codes C15.0 to C16.9) during the 12-
year period between 1995 and 2006, including on tumour
site, morphology, patient gender and diagnosis age. We
defined five tumour types, according to site and histology
(OSCC, OAC, JCA, NCGA, and 'all other' oesophago-gas-
tric cancers), motivated by previous research,[22] and as
previously described[23]. Because, OSCC management is
substantially different to that of the other oesophagogas-
tric cancers (because of a relatively prominent role of radi-
otherapy treatment) we excluded OSCC patients from
further analysis. More specifically, the following tumour
type operational definitions (based on ICD-10 site and
ICD-O morphology codes) were used:
• OSCC (defined in order to be excluded from further
analysis, as explained above): ICD-10 C150-9 and
ICD-O M80703 ('Squamous cell carcinoma', 88% of
cases in this category), or M80713, M80723, M80733,
M80743, M80943, M81233, M85603).
￿ OAC: ICD-10 C150-9 and ICD-O M81403 ('Adeno-
carcinoma', 92% of cases in this category) or M81443,
M81453, M82603, M83103, M84803, M84813 and
M84903.
￿ JCA: ICD-10 C160 and ICD-O M81403 ('Adenocar-
cinoma', 87% of cases in this category) or M81443,
M81453, M82103, M82603, M83103, M84803,
M84813 and M84903.
￿ NCGA: ICD-10 C161-9 and ICD-O M81403 ('Aden-
ocarcinoma', 83% of cases in this category) or
M81443, M81453, M82103, M82603, M84803,
M84813 and M84903.
￿ 'Other': All other tumours (principally 'Carcinoma',
70% in this category).
We measured patient socioeconomic status with an eco-
logical (i.e. small area) measure. Specifically, patient soci-
oeconomic status was assigned using the Index of
Multiple Deprivation (IMD) 2004 deprivation score of
their Lower Super Output Area (LSOA) of residence. IMD
is composed of different domains, including among oth-
ers economic, social, education, health and housing indi-
cators, and indicates the level of deprivation of residents
of a small area relative to the residents of other small
areas[24]. LSOA's are co-terminous small areas with simi-
lar socio-demographic characteristics (typically compris-
ing five Census Output Areas with about 1,500 residents).
This low level and 'homogenous' aggregation minimises
the potential for ecological fallacy (misattribution of indi-
vidual socioeconomic status using the 'average' socioeco-
nomic profile of a greater sample of individuals)[25].
Quintile groups using the national distribution of LSOABMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
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deprivation scores were used in subsequent analysis
(groups 1 to 5: 'least' to 'most' deprived respectively).
Information was available on surgical treatment within
six months from diagnosis, coded by Registry staff, using
the Office for Population and Censuses and Surveys, 4th
Revision (OPCS 4) classification system[26]. Curative sur-
gery was defined using appropriate excision surgery codes,
and palliative surgery defined as surgical placement of
stent or gastrojejunostomy. More specifically, the follow-
ing operational definitions (based on OPCS 4 codes) were
used: Curative surgery: G281-3, G288-9: partial excision of
stomach (33% of all curative surgery cases); G011-3,
G018-9: excision of oesophagus and stomach (25%);
G021, G023, G028-9: total excision of oesophagus (8%);
G271-5, G278-9: total excision of stomach (17%); G031,
G038-9: partial excision of oesophagus (16%); G041-3,
G048-9: open extirpation of lesion of oesophagus (1.7%);
G291-5, G298: open extirpation of lesion of stomach
(1.1%). 1.5% of all patients had more than one of the
above curative surgery codes. Palliative surgery: G119:
Open placement of prosthesis in oesophagus (81%);
G331: Bypass of stomach by anastomosis of stomach to
jejunum (19%). A patient had both palliative procedures.
We analysed these two types of palliative surgery sepa-
rately in interim analysis, but report the findings in an
aggregate fashion, both because disaggregated findings
were similar, and because the gastrojejunostomy group
was very small (less than a fifth of all palliative surgery).
Information was also available on chemotherapy and
radiotherapy treatment within six months from diagnosis
- whether with a curative or palliative intent.
We examined predictors of use of curative surgery, pallia-
tive surgery, chemotherapy, and radiotherapy (patients
could belong to one or more of these treatment groups);
as well as for 'combined' (within six months from diagno-
sis) use of both curative surgery and chemotherapy. We
did not consider any other combined treatment groups,
because of small numbers. For example, within six
months from their diagnosis, only 160 (1.1%) patients
were treated by both radiotherapy and curative surgery,
only 146 (1.0%) by all of curative surgery, chemotherapy
and radiotherapy; and only 85 (0.6%) by both curative
and palliative surgery.
In univariable analysis, proportions of patients in each
treatment group were calculated by age group (three
groups, 40-59, 60-74, and ≥75), gender, diagnosis period
(four triennial periods, 1995-7, 1998-2000, 2001-3, and
2004-6), deprivation group (1-5), and tumour type. Dif-
ferences between patient groups were examined with the
chi-squared test (for gender or tumour type), or linear
regression for ordinal variables (adjusting for age group,
diagnosis period or deprivation group as applicable).
In multivariable analysis, predictors of treatment use were
examined by logistic regression, with treatment status as
the binary dependent variable, and adjusting for gender,
age group, diagnosis period, deprivation group and
tumour type. We furthermore repeated all analysis by
sequentially including in models interaction terms for
deprivation and gender, deprivation and age group, and
deprivation and diagnosis period.
Stage information was principally limited to 44% (440/
1,009) of OAC patients diagnosed between 2004-6, using
the 5th Edition of the TNM classification, comprising
stages I-IV)[27]. For other cancer types and diagnosis peri-
ods, the number of patients with stage information was
negligible. For OAC patients diagnosed during 2004-6, we
examined predictors of stage ascertainment, and of
advanced stage (defined as stages III-IV). We subsequently
examined predictors of treatment use, again using multi-
variable logistic regression analysis, and compared the
degree of concordance of the findings relating to staged
OAC patients with the findings obtained from the 'all
cases' analysis for the same period.
Results
There were 14,077 patients with relevant oesophagogas-
tric cancers during the 12-year study period (5,112
oesophageal cancers other than OSCC, and 8,965 stom-
ach cancers). 9,653 (69%) of the patients were men. The
mean age at diagnosis was significantly greater for
women, by +5.6 (75.1 vs. 69.4), +3.5 (72.4 vs. 68.9) and
+2.0 (75.0 vs. 73.0) years for OAC, JCA and NCGA respec-
tively.
Overall during the study, 25% of all patients were treated
by curative surgery, 8% by palliative surgery, 20% by
chemotherapy, 11% by radiotherapy, and 5% by both cur-
ative surgery and chemotherapy (see Table S1 in Addi-
tional file 1). Between 1995-7 and 2004-6, curative
surgery use decreased by about a third (from 28% to 20%
of all patients, p < 0.001) and chemotherapy use increased
by more than three-fold (from 9% to 30%, p < 0.001).
Palliative surgery and radiotherapy use increased signifi-
cantly but slightly. These associations remained signifi-
cant in multivariable analysis (See Table S2 in Additional
file 2).
In both univariable and multivariable analysis, more
deprived patients were less likely to be treated with cura-
tive surgery, chemotherapy, and their combined use
(Table 1 and Figures 1, 2). These differences were particu-
larly prominent for chemotherapy use. For chemotherapy
use there is an apparent linear decrease in frequency of use
with increasing deprivation; however, for curative surgery
use, there appears to be a (non-linear) 'step' effect, with
socioeconomic variation mainly relating to the most (andBMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
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Table 1: Percentage of patients treated, by treatment and deprivation group
UNIVARIABLE ANALYSIS UNADJUSTED LOGISTIC REFRESSION MULTIVARIABLE ANALYSIS**
CURATIV
E 
SURGERY
N n % p* OR 95% CI p OR 95% CI p
Depr. 
Group cont.
0.97 0.94 1.00 0.034 0.96 0.93 0.99 0.009
'Affluent' 2,832 733 25.9% p = 0.034 Ref. Ref.
2 3,334 850 25.5% 0.98 0.87 1.10 1.01 0.9 1.15
3 3,647 943 25.9% 1.00 0.89 1.12 1.02 0.9 1.15
4 3,053 736 24.1% 0.91 0.81 1.02 0.93 0.82 1.06
'Deprived' 1,211 279 23.0% 0.86 0.73 1.00 0.83 0.70 0.98
14,077 3,541 25.2%
PALLIATI
VE 
SURGERY
Depr. 
Group cont.
0.96 0.91 1.00 0.074 0.96 0.91 1.00 0.076
'Affluent' 2,832 242 8.6% p = 0.074 Ref. Ref.
2 3,334 293 8.8% 1.03 0.86 1.23 1.04 0.87 1.25
3 3,647 321 8.8% 1.03 0.87 1.23 1.06 0.89 1.27
4 3,053 230 7.5% 0.87 0.72 1.05 0.91 0.75 1.10
'Deprived' 1,211 90 7.4% 0.86 0.67 1.11 0.94 0.73 1.22
14,077 1,176 8.4%
CHEMOT
HERAPY
Depr. 
Group cont.
0.90 0.87 0.93 < 0.001 0.90 0.87 0.93 < 0.001
'Affluent' 2,832 660 23.3% p < 0.001 Ref. Ref.
2 3,334 678 20.3% 0.84 0.74 0.95 0.88 0.76 1.01
3 3,647 701 19.2% 0.78 0.69 0.88 0.82 0.71 0.94
4 3,053 552 18.1% 0.73 0.64 0.82 0.76 0.66 0.88
'Deprived' 1,211 201 16.6% 0.65 0.55 0.78 0.65 0.53 0.79
14,077 2,792 19.8%
CUR. 
SURGERY 
+CHEMO
THERAPY
Depr. 
Group cont.
0.93 0.88 0.99 0.023 0.94 0.88 0.99 0.045
'Affluent' 2,832 165 5.8% p = 0.023 Ref. Ref.
2 3,334 206 6.2% 1.06 0.86 1.31 1.18 0.94 1.47
3 3,647 194 5.3% 0.91 0.73 1.12 0.99 0.79 1.24
4 3,053 161 5.3% 0.90 0.72 1.13 1.03 0.81 1.30
'Deprived' 1,211 52 4.3% 0.73 0.53 1.00 0.77 0.55 1.07BMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
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perhaps the one but most) deprived group. An apparent
deprivation gradient for palliative surgery use did not
reach significance, whilst no deprivation gradient was
apparent in multivariable analysis for radiotherapy use.
None of the interaction terms between deprivation and
each of gender, age group and diagnosis period were sig-
nificant, for any of the treatment groups, indicating that
the effect of deprivation on treatment use was similar in
both sexes, and in any age group and diagnosis period.
Older patients were significantly less likely to be treated
with any of the reviewed treatments except palliative sur-
gery, and these associations remained significant in mul-
tivariable analysis.
Men, in univariable analysis, were significantly more
likely to be treated by any of the reviewed treatments
except palliative surgery. However, in multivarible analy-
sis, men were more likely to be treated only with chemo-
therapy (p < 0.001), and palliative surgery (but not
significantly so, p = 0.092).
14,077 778 5.5%
RADIOTH
ERAPY
Depr. 
Group cont.
0.97 0.93 1.01 0.120 0.98 0.94 1.02 0.347
'Affluent' 2,832 324 11.4% p = 0.120 Ref. Ref.
2 3,334 354 10.6% 0.92 0.78 1.08 0.95 0.8 1.12
3 3,647 393 10.8% 0.93 0.80 1.09 0.99 0.84 1.17
4 3,053 293 9.6% 0.82 0.70 0.97 0.89 0.75 1.06
'Deprived' 1,211 132 10.9% 0.95 0.76 1.17 1.08 0.87 1.35
14,077 1,496 10.6%
Univariable analysis and unadjusted and adjusted Odds Ratio for treatment use by deprivation group (from multivariable logistic regression models, 
adjusting for age group, gender, diagnosis period and tumour type).
OR: Odds Ratio; 'Depr.': Deprivation; 'cont'; Continuous (variable); CI: Confidence Interval; 'Cur': Curative.
p*: From linear regression models, entering deprivation group as a continuous variable, as a test for trend.
p**: The full model outputs are presented in Table S2 in Additional file 2
Table 1: Percentage of patients treated, by treatment and deprivation group (Continued)
Percentage of patients treated (with curative surgery, pallia- tive surgery, chemotherapy, curative surgery and chemother- apy in combination, and radiotherapy) by deprivation group Figure 1
Percentage of patients treated (with curative sur-
gery, palliative surgery, chemotherapy, curative sur-
gery and chemotherapy in combination, and 
radiotherapy) by deprivation group. Continuous lines 
denote significant and dashed lines non-significant associa-
tions in univariable analysis.
Odds ratios for treatment use (curative surgery, palliative  surgery, chemotherapy, curative surgery and chemotherapy  in combination, and radiotherapy) by deprivation group Figure 2
Odds ratios for treatment use (curative surgery, pal-
liative surgery, chemotherapy, curative surgery and 
chemotherapy in combination, and radiotherapy) by 
deprivation group. Continuous lines denote significant and 
dashed lines non-significant associations in multivariable anal-
ysis adjusting for age group, gender, diagnosis period and 
tumour type.BMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
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Stage information was available for 440 of 1,009 (44%)
OAC patients diagnosed during 2004-6. Stage ascertain-
ment was significantly greater for patients <75 (53% vs
32%, p < 0.001) but was not associated with gender or
deprivation (data not shown). Advanced stage (i.e. stages
III or IV) was not significantly associated with age, gender
or deprivation. As observed in 'all patients' analysis, use of
curative surgery, and of chemotherapy, decreased with
increasing deprivation, but only approaching significance
(OR: 0.86, p = 0.134, and OR: 0.88, p = 0.129, respec-
tively). Similarly, there was less frequent chemotherapy
use in women, again only approaching significance (OR:
0.64, p = 0.114). Overall, comparing the effects of age,
gender and deprivation on use of any of the five reviewed
treatments among 'all' and 'staged' OAC patients during
2004-6 (15 comparison pairs in total), eight pairs of
observations were concordant for both effect direction
and significance level; five were concordant for effect but
not for level of significance; and two were discordant (in
relation to effect direction).
Discussion
There were substantial changes over time in the manage-
ment of over 14,000 oesophageal and stomach cancer
patients diagnosed over a 12-year period in the East of
England. During the study period, curative surgery use
decreased substantially (by over a quarter) and chemo-
therapy use increased dramatically (by more then three-
fold). Adjusting for other variables, more deprived
patients were less likely to be treated by curative surgery
and by chemotherapy, however this association was much
stronger for chemotherapy. Chemotherapy use was also
less likely in women.
Deprivation differences in use of curative surgery,
although statistically significant, were relatively limited in
both absolute and proportional terms (e.g. 26% com-
pared with 23% use, in least and most deprived patients
respectively). In contrast, socioeconomic treatment pat-
terning was much stronger for chemotherapy use (e.g.
23% compared with 17% use, in least and most deprived
patients respectively). Moreover, although the apparent
effect of deprivation status on frequency of chemotherapy
use was linear, no such consistent effect was observed for
curative surgery use. These observations mean that data
limitations (described below) could at least in theory be
responsible for the observed socioeconomic difference in
use of curative surgery. However, given the substantial
effect size of deprivation status on use of chemotherapy,
as well as its apparent linear effect, this is less likely to be
the case for the observed socioeconomic variation in
chemotherapy use, which is more likely to be genuine.
The main strengths of our study are its population-based
basis and the fact that it covers a substantial time period
and very large number of patients.
The main and most important limitation of our analysis is
the lack of information on stage at diagnosis for the great
majority of the patients. Population-based survival esti-
mates for oesophageal and stomach cancers have
remained poor and changed very little during the study
period[6-9]. This would strongly suggest a stable over
time distribution of stage among incident cases, that
could not account for the observed substantial reduction
over time in use of surgery and the dramatic increase in
use of chemotherapy. However, lack of stage information
poses certain interpretation challenges in relation to the
observed socioeconomic differences in use. Several non-
UK studies suggest that lower socioeconomic status indi-
viduals may have more advanced diagnosis stage[28,29].
This limitation has to be seen in the context of the popu-
lation-based nature and size of the dataset, and the study
period: There is very limited availability of stage informa-
tion for upper gastrointestinal cancers in population-
based datasets covering the same period in England,
although this weakness in cancer registration systems is
now being rapidly addressed. No significant association
between deprivation and stage at presentation was
observed among the subgroup of OAC patients for whom
stage information was available, but this finding may sim-
ply reflect lack of power to detect a significant association,
and is best considered as inconclusive. Nevertheless, if
more deprived patients in this dataset were presenting at
relatively more advanced stage, one could have expected
an association between increasing deprivation and
increasing use of palliative surgery. No such significant
trend was observed, in fact, there was an apparent trend in
the opposite direction, which however did not reach sig-
nificance. Therefore, even if they existed, potential depri-
vation group differences in stage at presentation are
unlikely to fully explain the observed socioeconomic gra-
dients in use of curative surgery and chemotherapy. Previ-
ous research also indicates that survival inequalities
cannot be fully explained by socioeconomic differences in
stage[13,14]. These interpretation challenges should be
addressed by further research.
Another limitation is the lack of information on patients'
co-morbidity status, which may vary between different
oesophago-gastric cancers,[30] and deprivation groups.
However, if more deprived patients had a greater co-mor-
bidity burden, one could again expect this to have mainly
influenced surgical treatment use (because of the greater
anaesthetic risk of patients with higher co-morbidity bur-
den). In contrast, socioeconomic inequalities in both the
use of surgery and the use of chemotherapy were observed
(and as noted above, socioeconomic variation in use wasBMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
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greater for chemotherapy). These observations would
indicate that potential socioeconomic differences in co-
morbidity status are unlikely to fully explain the observed
deprivation differences in treatment use.
Furthermore, we could not examine whether chemother-
apy or radiotherapy were used with a palliative or curative
intent. However, the observed increase in combined use
of curative surgery and chemotherapy suggests that most
of the increase over time in chemotherapy use could be
expected to have been in an adjuvant context - although
pre-operative chemotherapy will not have actually been
followed up by actual surgery in all patients, because of
inadequate response.
Treatment status information might have been incom-
plete (or inaccurate) for some patients - particularly in
relation to palliative interventions. However, this would
have only introduced non-differential error, and should
have not therefore biased the observed findings in rela-
tion to socioeconomic or gender variation (or its lack).
Such an assumption is both logical and supported by
empirical evidence from other 'routine data' sources[31].
Similarly, it is possible that changes during the study
period in data quality (including in the degree of treat-
ment status ascertainment) may at least in part be respon-
sible for some of the observed findings. However, there
has been a high degree of consistency over time in cancer
registration systems used in the UK, where cancer registra-
tion has been established over a number of decades. In
addition, potential improvements in capturing treatment
status could have perhaps explained the observed increase
in chemotherapy use but are very unlikely to be responsi-
ble for the observed decrease in use of curative surgery.
Furthermore, any changes over time in treatment status
ascertainment would have been non-differential between
patients of different gender and socioeconomic groups,
[31] and cannot therefore be responsible for the observed
gender and socioeconomic differences in use. For these
three reasons, we believe that potential secular changes in
data quality are unlikely to be responsible for the
observed findings.
We could not examine treatment use beyond six months
from diagnosis - however, given the poor prognosis of
oesophagogastric cancer, for most patients, treatments
that would have been administered beyond that period
are likely to have been palliative. Information about
whether patients were treated in private hospitals (for all
or part of their care) would have been useful. We had no
information about other aspects of treatment quality (for
example: chemotherapy or radiotherapy dose and regime;
treatment timeliness after diagnosis; and adequacy of sur-
gical excision). Information about other quality of care
aspects would have made the analysis more informative.
The observed decrease over time in use of curative surgery
is consistent with similar trends reported in two recent
national studies (which however also included OSCC in
analysis)[2,32]. More specifically, an England and Wales
audit including information about over 105,000 patients
indicated that 'cancer surgery' use in oesophagogastric
cancer decreased by nearly a third (from 28% to 20%)
between 1998 and 2005,[2] similar to our own findings.
Comparing our findings with this study, although we
defined tumour categories differently, we also found cur-
ative surgery rates being highest for patients with junc-
tional and stomach adenocarcinomas, and relatively
lower for OAC patients. Similarly, in Ireland, there was a
nearly two-fold reduction in curative surgery use between
patients diagnosed in 2000-1 compared with 1994-6[29].
These findings may reflect improved patient selection
because of better staging, either by endoscopic ultra-
sound, and/or CT and PET scanning[2,29].
Previous reports indicate a near doubling in use of 'either
chemotherapy or radiotherapy' between 1998 and 2005,
from 18% to 34%, without further dis-aggregation of this
figure into chemotherapy and radiotherapy[2]. Our find-
ings strongly indicate that the greatest rise in use of non-
surgical treatments for (non-OSCC) gastro-oesophageal
tumours relates to chemotherapy, probably reflecting
increasing peri-operative use in patients judged suitable
for curative surgery,[3,4] as also directly observed in our
study, with increasing trends in the combined use of
chemotherapy and curative surgery.
The findings would support the hypothesis that socioeco-
nomic differences in treatment use may be at least partly
responsible for survival inequalities among men with
oesophageal and stomach cancer, and, in relation to cura-
tive surgery, they are consistent with those from a popula-
tion-based study in The Netherlands[33].
Deprivation differences in curative surgery and in chemo-
therapy use were present in both men and women. This
provides no insights into reasons for the previously
reported better survival in most deprived women with
gastric cancer,[7] although potential differences in stage at
presentation between the two genders may be responsi-
ble. Most of the observed gender differences in treatment
use did not persist once the effect of other variables was
adjusted for in multivariable analysis, most likely reflect-
ing the fact that women patients were on average older
than men. Nevertheless, the observed lower chemother-
apy use in women, which persisted even in multivariable
analysis adjusting, among other variables, for age, is sur-
prising. As there were no significant gender differences in
use of both chemotherapy and curative surgery, the
observed differences might principally relate to use ofBMC Health Services Research 2009, 9:231 http://www.biomedcentral.com/1472-6963/9/231
Page 8 of 9
(page number not for citation purposes)
chemotherapy with a palliative intent, however, this
hypothesis would require further research.
Conclusions
Using East of England cancer registration data on the
management of oesophago-gastric cancer (other than
OSCC) during 1995-2006, we found that curative surgery
use decreased and chemotherapy use increased, reflecting
improvements in overall quality and appropriateness of
care. However, use of chemotherapy, in particular, was
less likely in more deprived patients and women. Further
research should aim to explore the potential influence of
differences in stage at diagnosis and in co-morbidity sta-
tus on variation in treatment use. It should also encom-
pass other aspects of healthcare quality, for example
treatment timeliness.
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